Organ-on-Chip Microphysiological Systems
Acronym for: OoC / MPS
Also known as: Human Liver-Chip / Lung-Chip, Microfluidic Vascularized Organoids, FDA Modernization Act 2.0 NAMs
Perfused microfluidic cell-culture devices lined with living primary or iPSC-derived human parenchymal cells, endothelial vasculature, and immune cells that recapitulate organ-level mechanical forces (fluid shear stress, cyclic breathing stretch) and human metabolic toxicity in vitro.
Architectural Role in Modern Life Science R&D
Over 89% of drugs that pass preclinical rodent, canine, and non-human primate toxicology studies still fail in human clinical trials, with drug-induced liver injury (DILI) and cardiotoxicity representing top causes of late-stage attrition. Following the passage of the US FDA Modernization Act 2.0 (which removed the statutory mandate for animal testing prior to human trials) and the 2024 FDA ISTAND qualification program, pharmaceutical teams pair Organ-on-Chip Microphysiological Systems (from Emulate, MIMETAS, CN Bio, and Hesperos) with computational PK/PD modeling to screen human-specific hepatotoxicity, blood-brain barrier penetration, and ADCC immunotherapy efficacy. Why does this matter for your lab? If you're scaling Organ-on-Chip Microphysiological Systems in production, we've found you can't treat it as a black box. You'll need tight wet-lab calibration, and we always recommend validating your pipeline against orthogonal assays before you lock in your budget.
Evaluation & Wet-Lab Integration Checklist
How do you evaluate Organ-on-Chip Microphysiological Systems without wasting six months? Start small. When we audit R&D informatics teams, we tell you to test three things first: prospective wet-lab accuracy (like SPR or Cryo-EM), native API sync with your ELN, and containerized GPU costs. Don't skip the retrospective benchmark. It's the fastest way to see if a vendor's model actually works on your proprietary targets.
Context
Over 89% of drugs that pass preclinical rodent, canine, and non-human primate toxicology studies still fail in human clinical trials, with drug-induced liver injury (DILI) and cardiotoxicity representing top causes of late-stage attrition. Following the passage of the US FDA Modernization Act 2.0 (which removed the statutory mandate for animal testing prior to human trials) and the 2024 FDA ISTAND qualification program, pharmaceutical teams pair Organ-on-Chip Microphysiological Systems (from Emulate, MIMETAS, CN Bio, and Hesperos) with computational PK/PD modeling to screen human-specific hepatotoxicity, blood-brain barrier penetration, and ADCC immunotherapy efficacy. Why does this matter for your lab? If you're scaling Organ-on-Chip Microphysiological Systems in production, we've found you can't treat it as a black box. You'll need tight wet-lab calibration, and we always recommend validating your pipeline against orthogonal assays before you lock in your budget.
Examples
- 1Emulate Human Liver-Chip benchmarking 27 known hepatotoxic and non-toxic small molecules with 87% sensitivity and 100% specificity, catching toxicities missed in preclinical animal models.
- 2Using MIMETAS OrganoPlate high-throughput 384-well microfluidic arrays to screen antibody-drug conjugate (ADC) vascular extravasation across 3D human tumor-vessel barriers.
- 3Connecting multi-organ liver, cardiac, and skeletal muscle chips (Hesperos) to measure parent drug and liver metabolite cardiotoxicity in a single recirculating serum-free medium.
Implementing Agents
AI agents that implement or utilize Organ-on-Chip Microphysiological Systems:
Emulate
Pioneer of the Zoë culture module and Human Liver-Chip accepted into the FDA ISTAND pilot program.
Pioneer of the Zoë culture module and Human Liver-Chip accepted into the FDA ISTAND pilot program.
MIMETAS
High-throughput pump-free OrganoPlate microfluidic platform compatible with standard 384-well automated liquid handlers.
High-throughput pump-free OrganoPlate microfluidic platform compatible with standard 384-well automated liquid handlers.
CN Bio Innovations
PhysioMimix microphysiological systems widely used for MASH/NASH metabolic liver disease modeling and FDA submissions.
PhysioMimix microphysiological systems widely used for MASH/NASH metabolic liver disease modeling and FDA submissions.
Common Industries
Related Terms
Learn More
Verified References & Citations (2)
- [1]
Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology across 870 chips.
- [2]
FDA accepts first Organ-on-Chip microphysiological system into the ISTAND Qualification Program for drug development tools.
FDA ISTAND Program Acceptance of Human Liver-Chip for Drug-Induced Liver Injury (U.S. Food and Drug Administration)